{"id":50316,"date":"2022-11-01T12:02:19","date_gmt":"2022-11-01T11:02:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/"},"modified":"2022-11-01T12:02:19","modified_gmt":"2022-11-01T11:02:19","slug":"receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/","title":{"rendered":"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST)"},"content":{"rendered":"
\n

SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, is expanding the potential clinical utility of RLS103 into epilepsy. A proof-of-concept clinical safety and efficacy study in epilepsy will be conducted under a second, recently opened IND application. The Phase 1b randomized, double-blind, placebo-controlled, crossover study will evaluate RLS103 in patients with photosensitive epilepsy as a model for REST. RLS103, a dry powder inhaled cannabidiol (CBD), is a first-in-class drug\/device combination product for the acute treatment of psychiatric and neurological disorders. Epilepsy study startup is underway.\n<\/p>\n

<\/a><\/p>\n

\n\u201cAs the parent of a child with epilepsy, I recognize the need for a product that can terminate a seizure as soon as possible, without sedation,\u201d said Mark Theeuwes, President and CEO of Receptor Life Science. \u201cRLS103 could address that need as the first non-scheduled, non-sedating seizure rescue therapy. Advancing our lead drug candidate, RLS103, into a second proof-of-concept clinical study demonstrates our continued commitment to treating central nervous system conditions in collaboration with FDA.\u201d\n<\/p>\n

\n\u201cMany patients with epilepsy have recognizable auras that precede a seizure,\u201d said Orrin Devinsky, MD, Professor of Neurology, Neurosurgery, and Psychiatry at NYU School of Medicine. \u201cA treatment capable of terminating a seizure at the aura stage would be a life-changing therapy for these patients. This study is designed to be the first proof-of-concept clinical trial of RLS103 in epilepsy, and will be a study of significant interest for epileptologists and patient communities.\u201d\n<\/p>\n

\nAccording to the Epilepsy Foundation, seizure disorder affects about 3.4 million people in the United States.\n<\/p>\n

\nAbout Receptor Life Sciences<\/b>\n<\/p>\n

\nReceptor Life Sciences is a pharmaceutical company that applies FDA-approved drug delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval, see www.receptorlife.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDavid Sheon
\n
dsheon@whitecoatstrategies.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, is expanding the potential clinical utility of RLS103 into epilepsy. A proof-of-concept clinical safety and efficacy study in epilepsy will be conducted under a second, recently opened IND application. The Phase 1b randomized, double-blind, placebo-controlled, crossover study will … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50316","6":"format-standard","7":"category-industry"},"yoast_head":"\nReceptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, is expanding the potential clinical utility of RLS103 into epilepsy. A proof-of-concept clinical safety and efficacy study in epilepsy will be conducted under a second, recently opened IND application. The Phase 1b randomized, double-blind, placebo-controlled, crossover study will ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-01T11:02:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221101005095\/en\/1618350\/21\/Receptor-Primary-SMALL.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST)\",\"datePublished\":\"2022-11-01T11:02:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/\"},\"wordCount\":372,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101005095\\\/en\\\/1618350\\\/21\\\/Receptor-Primary-SMALL.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/\",\"name\":\"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101005095\\\/en\\\/1618350\\\/21\\\/Receptor-Primary-SMALL.jpg\",\"datePublished\":\"2022-11-01T11:02:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101005095\\\/en\\\/1618350\\\/21\\\/Receptor-Primary-SMALL.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101005095\\\/en\\\/1618350\\\/21\\\/Receptor-Primary-SMALL.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/","og_locale":"en_US","og_type":"article","og_title":"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST) - Pharma Trend","og_description":"SEATTLE–(BUSINESS WIRE)–Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, is expanding the potential clinical utility of RLS103 into epilepsy. A proof-of-concept clinical safety and efficacy study in epilepsy will be conducted under a second, recently opened IND application. The Phase 1b randomized, double-blind, placebo-controlled, crossover study will ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-01T11:02:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221101005095\/en\/1618350\/21\/Receptor-Primary-SMALL.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST)","datePublished":"2022-11-01T11:02:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/"},"wordCount":372,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221101005095\/en\/1618350\/21\/Receptor-Primary-SMALL.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/","url":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/","name":"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221101005095\/en\/1618350\/21\/Receptor-Primary-SMALL.jpg","datePublished":"2022-11-01T11:02:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221101005095\/en\/1618350\/21\/Receptor-Primary-SMALL.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221101005095\/en\/1618350\/21\/Receptor-Primary-SMALL.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/receptor-life-sciences-opens-second-investigational-new-drug-ind-application-with-fda-for-rls103-inhaled-dry-powder-cbd-for-the-treatment-of-rapid-epileptic-seizure-termination-rest\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Receptor Life Sciences Opens Second Investigational New Drug (IND) Application with FDA for RLS103 (Inhaled Dry Powder CBD) for the Treatment of Rapid Epileptic Seizure Termination (REST)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50316","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50316"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50316\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50316"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50316"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50316"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}